What’s two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the previous three. Drugmakers had lobbied for the change, but the timing–and the wording–are bound to be controversial.
I have been building forums to promote the life sciences community for over 10 years. I enjoy exploring the issues, individuals and companies impacting the life/med/health tech community, and celebrating the innovators, entrepreneurs and policy makers who are actively working to build the community.
The acquisition of dialysis company Gambro last September continues to fuel Baxter International’s ($BAX) sales growth as it preps to spin out its biopharma division in 2015. But despite some stop-gap measures, it’s not likely that Baxter will actually be able to meet the demand for its dialysis products until additional manufacturing capacity opens up in 2016.
Mercom Capital Group, llc, a global communications and consulting firm, today released its report on funding and mergers and acquisitions (M&A) activity in the Healthcare Information Technology (IT) sector for the third quarter of 2014. Mercom’s comprehensive report covers deals of all sizes in Healthcare IT across the globe.
National Institutes of Health director Dr. Francis Collins today announced a new national initiative, the National Center of Excellence for Mobile Sensor Data-to-Knowledge (MD2K), focused on developing computational tools to facilitate the collection and analysis of large-scale health data generated by mobile and wearable sensors. Computer scientists Deepak Ganesan and Benjamin Marlin will co-lead the…
Following Shire plc’s (“Shire”) waiver of the three-day notice period, AbbVie Inc. (“AbbVie”) (NYSE: ABBV) announces today its Board of Directors’ withdraws its recommendation made on July 18, 2014 regarding the proposed Shire transaction and recommends that stockholders vote against the transaction.
Pentamer Pharmaceuticals today announced that it has begun a crowdfunding campaign for the development of its Ebola vaccine. Dr. Stephen Hall, the Founder and CEO of Pentamer, developed a vaccine technology called NodaVax that has produced protective vaccines against other pathogens like Anthrax.